Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CARANASDAQ:ENTXNASDAQ:GNLXNASDAQ:SKYE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$15.19$8.13▼$31.32$24.33M0.4123,653 shs237,144 shsENTXEntera Bio$2.15-3.2%$1.91$1.41▼$2.79$97.66M1.5176,207 shs8,407 shsGNLXGenelux$2.96+3.9%$2.98$1.60▼$5.89$111.70M-0.33210,780 shs106,656 shsSKYESkye Bioscience$1.81+1.1%$1.66$1.14▼$13.44$56.07M1.74357,307 shs287,465 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics0.00%0.00%+9.69%+6.40%-39.53%ENTXEntera Bio+1.61%-0.67%+36.73%-8.85%-9.59%GNLXGenelux+23.21%+17.81%+37.07%-33.39%-24.78%SKYESkye Bioscience-1.65%-12.25%+49.17%-43.19%-85.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARACara Therapeutics3.4166 of 5 stars3.05.00.04.20.60.80.0ENTXEntera Bio1.5507 of 5 stars3.54.00.00.00.00.80.0GNLXGenelux1.7314 of 5 stars3.62.00.00.03.20.00.0SKYESkye Bioscience1.4414 of 5 stars3.51.00.00.03.40.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics 2.00Hold$83.52∞ UpsideENTXEntera Bio 3.00Buy$10.00365.12% UpsideGNLXGenelux 3.20Buy$17.75499.66% UpsideSKYESkye Bioscience 3.00Buy$16.60817.13% UpsideCurrent Analyst Ratings BreakdownLatest CARA, GNLX, SKYE, and ENTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025GNLXGeneluxBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSpeculative Buy ➝ Speculative Buy$25.00 ➝ $23.003/31/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/25/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/21/2025SKYESkye BioscienceCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $14.003/21/2025SKYESkye BioscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/18/2025ENTXEntera BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.002/28/2025SKYESkye BioscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform(Data available from 5/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00ENTXEntera Bio$181K539.53N/AN/A$0.36 per share5.97GNLXGenelux$8K13,961.95N/AN/A$0.73 per share4.05SKYESkye BioscienceN/AN/AN/AN/A($0.17) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%5/12/2025 (Estimated)ENTXEntera Bio-$8.89M-$0.25N/AN/AN/AN/A-107.24%-92.29%5/9/2025 (Estimated)GNLXGenelux-$28.30M-$0.96N/AN/AN/AN/A-105.05%-80.16%N/ASKYESkye Bioscience-$37.65M-$0.72N/AN/AN/AN/A-45.78%-37.44%N/ALatest CARA, GNLX, SKYE, and ENTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025ENTXEntera Bio-$0.07-$0.06+$0.01-$0.06N/AN/A5/8/2025Q1 2025GNLXGenelux-$0.24-$0.21+$0.03-$0.21N/AN/A5/8/2025Q1 2025SKYESkye Bioscience-$0.31-$0.28+$0.03-$0.28N/AN/A3/28/2025Q4 2024ENTXEntera Bio-$0.08-$0.06+$0.02-$0.06$0.04 million$0.04 million3/28/2025Q4 2024GNLXGenelux-$0.17-$0.26-$0.09-$0.26N/AN/A3/20/2025Q4 2024SKYESkye Bioscience-$0.30-$0.24+$0.06-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/AGNLXGeneluxN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.774.71ENTXEntera BioN/A6.616.61GNLXGeneluxN/A6.476.47SKYESkye BioscienceN/A14.1914.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%ENTXEntera Bio14.11%GNLXGenelux37.33%SKYESkye Bioscience21.09%Insider OwnershipCompanyInsider OwnershipCARACara Therapeutics3.10%ENTXEntera Bio10.90%GNLXGenelux9.30%SKYESkye Bioscience3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics804.57 million4.43 millionOptionableENTXEntera Bio2045.42 million31.88 millionOptionableGNLXGenelux1037.74 million31.33 millionNot OptionableSKYESkye Bioscience1130.98 million29.43 millionOptionableCARA, GNLX, SKYE, and ENTX HeadlinesRecent News About These CompaniesSkye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in ObesityMay 8 at 4:01 PM | globenewswire.comBraidwell LP Buys Shares of 825,732 Skye Bioscience, Inc. (NASDAQ:SKYE)May 8 at 6:30 AM | marketbeat.comSkye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025May 7 at 7:00 AM | globenewswire.comWhy Skye Bioscience, Inc.’s (SKYE) Stock Is Down 5.53%May 7 at 6:32 AM | aaii.comSchonfeld Strategic Advisors LLC Acquires 463,644 Shares of Skye Bioscience, Inc. (NASDAQ:SKYE)May 6 at 4:48 AM | marketbeat.comSkye Bioscience to Participate in May Investment and Medical ConferencesApril 29, 2025 | globenewswire.comSkye Bioscience announces inducement grant under Nasdaq listing ruleApril 28, 2025 | markets.businessinsider.comSkye Bioscience Inc.April 26, 2025 | barrons.comSkye Bioscience Grants Stock Options to New Employee Under 2024 Inducement Equity Incentive PlanApril 25, 2025 | quiverquant.comSkye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 25, 2025 | globenewswire.comRx Rundown: Merck, the CDC, GSK and moreApril 18, 2025 | mmm-online.comWilliam Blair Predicts Skye Bioscience Q2 EarningsApril 18, 2025 | marketbeat.comA Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash ValueApril 16, 2025 | seekingalpha.comSkye Bioscience announces new preclinical data for nimacimabApril 15, 2025 | markets.businessinsider.comSkye Bioscience Stock Rises on Preclinical Data for Weight Loss DrugApril 15, 2025 | marketwatch.comSkye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal ModelsApril 15, 2025 | benzinga.comSkye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical ModelApril 15, 2025 | globenewswire.comSkye Bioscience to Conduct Meetings at Piper Sandler ConferenceApril 14, 2025 | globenewswire.comWhy Skye Bioscience, Inc.’s (SKYE) Stock Is Down 12.88%April 1, 2025 | aaii.comSkye Bioscience promotes Tu Diep to COO postMarch 25, 2025 | thepharmaletter.comEarnings call transcript: Skye Bioscience Q4 2024 highlights financials, product progressMarch 22, 2025 | uk.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCARA, GNLX, SKYE, and ENTX Company DescriptionsCara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Entera Bio NASDAQ:ENTX$2.15 -0.07 (-3.15%) As of 03:59 PM EasternEntera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Genelux NASDAQ:GNLX$2.96 +0.11 (+3.86%) As of 04:00 PM EasternGenelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Skye Bioscience NASDAQ:SKYE$1.81 +0.02 (+1.12%) As of 04:00 PM EasternSkye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend What the ExtraHop Deal Means for CrowdStrike DoorDash’s Uptrend Is Gaining Momentum in 2025 Why Flutter Entertainment May Be a Resilient Sports Betting Stock OXY Stock Rebound Begins Following Solid Earnings Beat Is Energy Transfer Undervalued or a Value Trap? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
